Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00169507 |
Evaluate the immunological memory induced by 4 doses of GSK Biologicals' 11valent pneumococcal vaccine; study antibody persistence 30 months after the 4 dose vaccination with GSK Biologicals' 11-valent pneumococcal vaccine in Undeca-Pn-010 study.
Condition | Intervention | Phase |
---|---|---|
Prophylaxis Pneumococcal Vaccine |
Biological: Pneumococcal (vaccine) |
Phase III |
Study Type: | Interventional |
Study Design: | Prevention, Non-Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Phase III Multicentric Open Study to Evaluate Immunological Memory Induced by 3-Dose Primary Vaccination Followed by Booster Dose of GSK Biologicals' 11-Valent Conjugate Pneumococcal Vaccine Compared to Unprimed Subjects by Giving 1 Dose of Aventis Pasteur's Pneumo 23 |
Estimated Enrollment: | 100 |
Primed group: 50 subjects who previously received 4 doses of GSK Biologicals' 11Pn-PD vaccine will receive 1 dose of Pneumo 23 Unprimed group (Control): 50 subjects who received GSK Biologicals' Havrix™ vaccine will receive 1 dose of Pneumo 23
Ages Eligible for Study: | 31 Months to 57 Months |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion criteria: Male or female who participated in Undeca-Pn-010 study, were part of the blood subset and received 4 doses of GSK Biologicals' 11Pn-PD vaccine, or Havrix vaccine. Exclusion criteria: Use of any investigational or non-registered drug or vaccine other than the study vaccine within 30 days preceeding the first dose of study vaccine, or planned use during the study period. Administration of any additional pneumococcal vaccine since study end of Undeca-Pn-010 (347414/010)
Slovakia | |
GSK Investigational Site | |
Nova Dubnica, Slovakia, 018 51 | |
GSK Investigational Site | |
Dubnica Nad Vahom, Slovakia, 018 41 | |
GSK Investigational Site | |
Povazska Bystrica, Slovakia, 017 01 | |
GSK Investigational Site | |
Puchov, Slovakia, 020 01 |
Study Director: | GSK Clinical Trials | GlaxoSmithKline |
Responsible Party: | GSK ( Study Director ) |
Study ID Numbers: | 104083 |
Study First Received: | September 12, 2005 |
Last Updated: | October 9, 2008 |
ClinicalTrials.gov Identifier: | NCT00169507 |
Health Authority: | Slovakia: State Institute for Drug Control |